VVOS vs XRAY

For growth investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger pick with 8. 9% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Analysts rate DENTSPLY SIRONA Inc. (XRAY) a "Hold" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, DENTSPLY SIRONA Inc.

(XRAY) delivered a total return of -80. 1%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: XRAY returned -74. 5% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 74β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 142% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Vivos Therapeutics, Inc. (VVOS) carries a lower debt/equity ratio of 19% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vivos Therapeutics, Inc.

(VVOS) is pulling ahead at 8. 9% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 80. 1% year-over-year, compared to 33. 0% for DENTSPLY SIRONA Inc.. Over a 3-year CAGR, XRAY leads at -2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DENTSPLY SIRONA Inc.

(XRAY) is the more profitable company, earning -16. 3% net margin versus -74. 1% for Vivos Therapeutics, Inc. — meaning it keeps -16. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XRAY leads at 6. 8% versus -74. 3% for VVOS. At the gross margin level — before operating expenses — VVOS leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, XRAY (5.

9% yield) pays a dividend. VVOS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74)). DENTSPLY SIRONA Inc. (XRAY) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VVOS: -99. 7%, XRAY: -74. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VVOS is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock. XRAY pays a dividend while VVOS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.